Biomerica Inc (BMRA)

Death hour is over,let the buying volume surges begin not seeing demand yet tho

All insurance companies/Medicare/ect are not only going to approve this,they are going to require it done first before any prescription or procedure(just like they do with everything,delay and try cheaper alternatives first,it can save them a fortune)

This ran to $10.00 from here last January on lessor news

They were just waiting on pricing approval,already had manufacturers/distributors/sales force in place,not only do they have the test they provide a dietitian screening and suggested diet to solve the ibs problem,not everyone is going to need drugs to solve the illness but everybody is going to need the test!
https://finviz.com/news/220865/biomerica-expands-contract-development-and-manufacturing-services-to-meet-growing-market-demand

Bought 2.50/2.42/2.43/2.44 ,95% of the time this runs on news and this news is really good,sets them profiting big from here on out! Should be golden to run after the last 30k shares to short are gone,I am thinking as death hr is ending (11:15-11:30)it will run up .
Good skill everyone !

Forgot about this one

United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® Ulcer Test for Home Use
10-minute home test enables detection of Helicobacter pylori, a leading cause of peptic ulcers, dyspepsia, and gastric cancer
H. pylori linked to approximately 80% of gastric cancer cases; classified as a Class 1 carcinogen by the World Health Organization
Gastric cancer ranks as the fifth most common cancer globally and the fourth leading cause of cancer-related deaths
IRVINE, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced diagnostic solutions, today announced that the United Arab Emirates (UAE) Ministry of Health and Prevention has approved Biomerica’s Fortel® Ulcer Test for home use. This marks a milestone in expanding access to accurate, easy-to-use diagnostic tools for one of the leading causes of gastric disease in the region.

The Fortel® Ulcer Test is a 10-minute rapid diagnostic test that detects antibodies to Helicobacter pylori (H. pylori), a bacterium responsible for peptic ulcers, dyspepsia, and a significant portion of gastric cancer cases. With this new regulatory approval, individuals across the UAE can now self-administer the test in the comfort and privacy of their own homes.

A Widespread and Dangerous Infection

H. pylori affects approximately 41% of the UAE population, with higher prevalence among certain age and ethnic groups. If left untreated, up to 20% of infected individuals may develop serious complications such as peptic ulcers, chronic digestive pain, or gastric malignancies. Up to 80% of gastric cancer cases are linked to H. pylori infection, making it one of the most concerning infectious cancer risk factors. In recognition of its global impact, the World Health Organization (WHO) has classified H. pylori as a Class 1 carcinogen and listed it among the top antibiotic-resistant bacterial threats to human health.

Expanded Access and Regional Impact

With home-use approval now in place, Biomerica is partnering with UAE-based distributors and healthcare providers to make the Fortel® Ulcer Test available at pharmacies, clinics, and online platforms. This approval strengthens Biomerica’s growing presence in the Middle East, building on the successful regional launch of the EZ Detect™ Colon Disease Test and other diagnostics designed for early detection and better patient outcomes.

“With this home-use approval, we’re giving people direct access to a reliable tool for early detection of a dangerous infection that could result in serious complications,” said Zack Irani, CEO of Biomerica. “This can help drive earlier and more effective medical treatment and potentially save lives.”

Committed to Early Detection and Better Health Outcomes

Biomerica remains focused on delivering affordable, innovative diagnostic tools that improve patient outcomes through early disease detection. The Fortel® Ulcer Test exemplifies an easy to implement solution in the fight against H. pylori-related illnesses and reflects the Company’s mission to improve global health with accessible and effective diagnostics.

About Biomerica (NASDAQ: BMRA)

Biomerica, Inc. (www.biomerica.com) is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (in home and in physicians' offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica primarily focuses on gastrointestinal and inflammatory diseases where the Company has multiple diagnostic and therapeutic products in development.

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by Biomerica) contains statements that are forward-looking, such as statements relating to the Company’s current and future sales, revenues, overhead, expenses, cost of goods, operations and earnings, efficacy of the Company’s products and tests including the Fortel® Ulcer Test, FDA and/or international regulatory authorization for the Company’s products to be marketed and sold, including the Fortel® Ulcer Test, and the Company’s other current and future products, the possible expansion in to other markets, uniqueness of the Company’s products, accuracy of the Company’s tests and products, pricing of the Company’s test kits, domestic and/or international market adoption and acceptance and demand for the Company’s products including the Fortel® Ulcer Test, future use of the Company's products by physicians to treat their patients, potential revenues from the sale of current or future products. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results, in the future, including, without limitation: earnings and

Ok then $10.00, this is going to go up fast an firious at some point $$$$$

$$5 is not impossible

You bet👍

BMRA: Monster THANKS, Admiral H-C, Dude --- for the heads-up, Bro!!! (LOVE this stuff!!!)

We bought this today, loaded! This company may soar to the moon! $$$$$$

BMRA: Looks good!!

Holding tight after market. Low issues shared could potentially be a 10 bagger

BMRA: Heck, anything affiliated with the UAE over there is gonna get big attention!!

great dip now 0.65

news was good today

BMRA: Hey, K-N-R, it sure looks that way!!

0.72 add.

bounce time

BMRA: WOW!! Rough ride this Wall Street morning, Dude!! (That's ME, below, tryin' to keep pace with yah, Boss!!)

Nice volume looks liken.67 will hold for next round but Caution as always 

See if it holds at least .67 can do another round doesn't hold then wait for .50 to .53

bmra....................................https://stockcharts.com/h-sc/ui?s=bmra&p=W&b=5&g=0&id=p86431144783

pretty good news release id say

BMRA: But ya banked some coin, Bro!! (I've been takin' YOUR sage advice for months now, on HOW to play this Wall Street CASINO.)

I still DO like their NEWS here today. (They got that HALF-MILE-HIGH building over there!!)
https://en.wikipedia.org/wiki/Burj_Khalifa
////////////////////////////////////////////////////////////////////////////////////////////

Took 80% off $1.15- $1.18 unless followed through will be all out average .88 so $.95 out 

give us 2

holy shi_ ..... LET'S GOOOOO

looking good breakout of $1.29 solid and off to $2 land should be a done deal

BMRA; Excuse me for a minute, my PROSTATE wants to take a PISS again!!!! (And my "Big-Gulp-Coffee" from 7/11 15-minutes ago didn't help it EITHER!!!)

coming $2+ today still ?

under fire

It looks as though it will open back up in the $1.32 range

$1.18 halt 

BMRA: My BLADDER woke me up!!! (Who says that???)

Yes lots of revenues potential immediately see a resistance zone all the way up $2.75 to $2.96 if they really let the goose loose. See what happens US contracts on the way 

Insiders loaded back on 12/17 with millions of shares @ $0.31. They knew this was gonna happen. https://www.otcmarkets.com/stock/BMRA/disclosure

United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® PSA Screening Test to Detect an Early Sign of Prostate Cancer
- 10-Minute PSA Test for Early Detection of Prostate Specific Antigen (PSA), an Early Warning Sign of Prostate Cancer

- Prostate Cancer: The Second Most Common Cancer in Men Globally

IRVINE, Calif., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of innovative diagnostic solutions, is proud to announce that its Fortel® Prostate Specific Antigen (PSA) Screening Test has received approval from the United Arab Emirates Ministry of Health and Prevention (MOHAP).

The Fortel® PSA Screening Test is a user-friendly diagnostic tool that provides accurate results in just 10 minutes using a simple finger-prick blood sample. By measuring elevated PSA levels, a recognized early marker of prostate disease, the test can enable early detection of prostate cancer and other prostate-related conditions. This rapid and accessible approach aims to enhance proactive health management, reduce the burden on healthcare systems, and improve patient outcomes.

Strategic Expansion in the Middle East

This milestone approval is part of Biomerica’s strategic initiative to expand its footprint in the Middle East, where prostate cancer is increasingly recognized as a critical public health concern. Building on its success in the region with the EZ Detect Colon Disease At-Home Screening Test, which received government insurance reimbursement in Dubai, Biomerica is working to replicating this achievement with the Fortel® PSA test. The Company has established partnerships with leading distributors and secured key regulatory approvals to make early cancer detection more accessible to patients in the region.

Proven Performance

The Fortel® PSA test has demonstrated outstanding performance in rigorous evaluations:

A study reported 100% sensitivity, 95% specificity, and 97.5% accuracy, aligning with laboratory reference methods.
Research conducted at the Faculty of Medicine, Ain Shams University in Egypt, further validated the test’s effectiveness, achieving 97.2% sensitivity, 96.2% specificity, and 96.7% accuracy.
These results highlight the Fortel® PSA test as a reliable and efficient tool for early detection.

The Growing Global and Regional Impact of Prostate Cancer

Prostate cancer is the second most common cancer among men worldwide, with 1.4 million new cases diagnosed and 375,000 deaths reported globally in 20201. Alarmingly, one new case is diagnosed every two minutes2. While extensive research and advancements in early detection have been made in Europe and North America, prostate cancer has become increasingly recognized as a significant public health challenge in the Middle East. The disease varies in prevalence and severity across different regions, age groups, ethnicities, and races and there remains a gap in comprehensive studies within the Middle East3.

Looking Ahead: Expanding Access to Life-Saving Diagnostics

Biomerica is reinforcing its commitment to expanding access to innovative diagnostic solutions in the Middle East. The company’s vision remains focused on providing affordable, accurate, and accessible tools to aid in the early detection and treatment of critical diseases like prostate cancer.

https://uroweb.org/guidelines/prostate-cancer/chapter/epidemiology-and-aetiology%E2%80%8B
https://zerocancer.org/about-prostate-cancer/facts-statistics
Mutlay Sayan et al. Prostate Cancer Awareness in the Middle East: A Cross-Sectional International Study. JCO Glob Oncol 10, e2400171(2024).
About Biomerica (NASDAQ: BMRA)

Biomerica, Inc. (www.biomerica.com) is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (in home and in physicians' offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica primarily focuses on gastrointestinal and inflammatory diseases where the Company has multiple diagnostic and therapeutic products in development.

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by Biomerica) contains statements that are forward-looking, such as statements relating to the Company’s current and future sales, revenues, overhead, expenses, cost of goods, operations and earnings, efficacy of the Company’s products and tests, FDA and/or international regulatory authorization for the Company’s products to be marketed and sold, including the Fortel PSA product, and the Company’s other current and future products, the possible expansion in to other markets, uniqueness of the Company’s products, accuracy of the Company’s tests and products, pricing of the Company’s test kits, domestic and/or international market adoption and acceptance and demand for the Company’s products, future use of the Company's products by physicians to treat their patients, potential revenues from the sale of current or future products. Such forward-looking information involves impo

$1.07 start cashing out some

97 + 177%

Yes my bad zone it's in now is .74 to $1.29 let the goose loose.

.83 resistance see if .53 to .57 new support 

Early morning jackpot prostate news .80 +'120%

BMRA: And MONSTER news over in the ARABIC world for this PUPPY!!!

BMRA.............https://stockcharts.com/h-sc/ui?s=BMRA&p=W&b=5&g=0&id=p86431144783

They vote on a RS next Friday the 13th - not a good omen IMO

BMRA...................https://stockcharts.com/h-sc/ui?s=BMRA&p=W&b=5&g=0&id=p86431144783

Most volume in a year .. potential here?

BMRA...................https://stockcharts.com/h-sc/ui?s=BMRA&p=W&b=5&g=0&id=p86431144783